Business in the Burbs

Regeneron reports wider 4Q loss

February

Regeneron Pharmaceuticals Inc., a biotech company in Eastview, reported a net loss of $31.5 million, or 40 cents per share, during the fourth quarter. That compared to a net loss of $13.1 million, or 19 cents per share, a year earlier. Total revenues decreased to $55.8 million in the fourth quarter from $64.7 million a year earlier. Arcalyst, Regeneron’s only marketable drug, was approved last year for treatment of a rare auto-inflammatory condition known as CAPS. Regeneron said that it expects shipments of Arcalyst to exceed $20 million this year.

This entry was posted on Thursday, February 26th, 2009 at 2:11 pm by Jay Loomis. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Earnings

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.